Nimesulide

The medicines are indicated for usage as a second line treatment option for acute pain and primary dysmenorrhea. Credit: Kmpzzz / Shutterstock.com. Helsinn Group has renewed a distribution and licence agreement with Angelini Pharma for the commercialisation of AULIN and MESULID (Nimesulide) to treat acute short-term pain in six European countries. The territories covered under the renewed deal include Bulgaria, the Czech Republic, Hungary, Poland, Romania and the Slovak Republic. The non-selective, non-steroidal anti-inflammatory drugs AULIN and MESULID are offered on prescription as an oral tablet and granules for oral suspension. They are indicated for usage as a second-line treatment option for acute pain and primary dysmenorrhea. AULIN gel, also marketed under the brand name AulinDol, is available on prescription or over the counter. See Also: FDA accepts Sanofi’s Sarclisa sBLA for priority review South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s It is intended to provide symptomatic relief of pain linked to sprains and acute traumatic tendinitis. Helsinn Group CEO Dr Melanie Rolli stated: “We are pleased to have signed this agreement with Angelini and honoured to maintain our ongoing collaboration. “Our long-standing partnership with Angelini exemplifies how Helsinn fosters relationships and alliances to deliver essential products to patients. We appreciate their extensive reach in these countries, which enables patient access to this much-needed treatment.” Angelini Pharma International Operations executive vice-president Erik Lommerde stated: “We are delighted to renew our partnership with Helsinn. “This collaboration is built on a foundation of mutual trust, highlighted by our shared commitment to professional excellence, in-depth product knowledge, and high-quality service. This alliance is crucial for both parties and represents a strong business relationship.” In May 2023, Angelini Pharma and JCR Pharmaceuticals signed a global development and commercialisation agreement focused on developing novel biologic therapies. This collaboration utilises J-Brain Cargo technology to address epilepsy. JCR Pharmaceuticals received research expense reimbursements, upfront payments and milestone payments of $505.5m, in addition to tiered royalties on net product sales post-approval.